These Analysts Just Made An Incredible Downgrade To Their Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) EPS Forecasts
These Analysts Just Made An Incredible Downgrade To Their Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) EPS Forecasts
The analysts covering Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Revenue and earnings per share (EPS) forecasts were both revised downwards, with the analysts seeing grey clouds on the horizon.
报道石家庄以岭药业有限公司(SZSE:002603)的分析师今天对今年的法定预测进行了实质性修订,从而向股东传递了一定负面情绪。收入和每股收益(EPS)的预测均向下修正,分析师认为灰云即将出现。
Following the downgrade, the current consensus from Shijiazhuang Yiling Pharmaceutical's six analysts is for revenues of CN¥11b in 2024 which - if met - would reflect a substantial 28% increase on its sales over the past 12 months. Per-share earnings are expected to soar 244% to CN¥0.93. Prior to this update, the analysts had been forecasting revenues of CN¥13b and earnings per share (EPS) of CN¥1.48 in 2024. Indeed, we can see that the analysts are a lot more bearish about Shijiazhuang Yiling Pharmaceutical's prospects, administering a measurable cut to revenue estimates and slashing their EPS estimates to boot.
下调评级后,石家庄以岭药业的六位分析师目前的共识是,2024年的收入为110亿元人民币,如果达到,这将反映其在过去12个月中销售额大幅增长28%。预计每股收益将飙升244%,至0.93元人民币。在本次更新之前,分析师一直预测2024年的收入为130亿元人民币,每股收益(EPS)为1.48元人民币。事实上,我们可以看出,分析师对石家庄以岭制药的前景更加悲观,他们大幅削减了收入预期,并下调了每股收益预期。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240505/0-d569a322c20de5c5682358c803e68891-0-92b4f5bafabfc4a9d3125cb319ce8720.png/big)
It'll come as no surprise then, to learn that the analysts have cut their price target 26% to CN¥20.09.
因此,得知分析师已将目标股价下调26%至20.09元人民币也就不足为奇了。
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's clear from the latest estimates that Shijiazhuang Yiling Pharmaceutical's rate of growth is expected to accelerate meaningfully, with the forecast 28% annualised revenue growth to the end of 2024 noticeably faster than its historical growth of 16% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 14% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Shijiazhuang Yiling Pharmaceutical is expected to grow much faster than its industry.
现在从大局来看,我们理解这些预测的方法之一是看看它们与过去的表现和行业增长估计相比如何。从最新估计中可以明显看出,石家庄以岭药业的增长率预计将大幅加快,预计到2024年底的年化收入增长率为28%,明显快于其过去五年中每年16%的历史增长。相比之下,同行业的其他公司预计收入每年将增长14%。考虑到收入增长的预测,很明显,石家庄以岭药业的增长速度预计将比其行业快得多。
The Bottom Line
底线
The most important thing to take away is that analysts cut their earnings per share estimates, expecting a clear decline in business conditions. Unfortunately, analysts also downgraded their revenue estimates, although our data indicates revenues are expected to perform better than the wider market. Given the scope of the downgrades, it would not be a surprise to see the market become more wary of the business.
要了解的最重要的一点是,分析师下调了每股收益预期,预计业务状况将明显下降。不幸的是,分析师也下调了收入预期,尽管我们的数据显示收入表现预计将好于整个市场。考虑到下调评级的范围,看到市场对该业务变得更加警惕也就不足为奇了。
As you can see, the analysts clearly aren't bullish, and there might be good reason for that. We've identified some potential issues with Shijiazhuang Yiling Pharmaceutical's financials, such as the risk of cutting its dividend. Learn more, and discover the 1 other concern we've identified, for free on our platform here.
如你所见,分析师显然并不看涨,这可能是有充分理由的。我们已经发现石家庄以岭制药的财务状况存在一些潜在问题,例如削减股息的风险。在我们的平台上免费了解更多,并发现我们确定的另外一个问题。
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.
当然,看到公司管理层将大量资金投资于股票与了解分析师是否在下调预期一样有用。因此,您可能还希望搜索这份内部人士正在购买的免费股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。